telcagepant and Acute-Disease

telcagepant has been researched along with Acute-Disease* in 3 studies

Reviews

2 review(s) available for telcagepant and Acute-Disease

ArticleYear
Efficacy, safety, and tolerability of telcagepant in the treatment of acute migraine: a meta-analysis.
    Pain practice : the official journal of World Institute of Pain, 2015, Volume: 15, Issue:2

    Although triptans are widely used for treating acute migraine, they are contraindicated or not effective in a large proportion of patients. Hence, alternative treatments are needed. Calcitonin gene-related peptide receptor antagonists, such as telcagepant, have been under investigation as a treatment for acute migraine. A meta-analysis of the efficacy of telcagepant vs. placebo and triptans (zolmitriptan or rizatriptan) was performed. Randomized controlled trials were indentified from databases using the following search terms: migraine; calcitonin gene-related peptide; calcitonin gene-related peptide receptor antagonists; efficacy; safety, and telcagepant. The primary outcome measure was pain freedom 2 hours after first treatment. The secondary outcome measure was pain relief 2 hours after first treatment. Eight trials were included in the meta-analysis (telcagepant = 4011 participants). The difference in pain freedom at 2 hours significantly favored telcagepant over placebo (odds ratio = 2.70, 95% confidence interval = 2.27-3.21, P < 0.001) and triptans over telcagepant (odds ratio = 0.68, 95% confidence interval = 0.56-0.83, P < 0.001). The difference in pain relief at 2 hours significantly favored telcagepant over placebo (odds ratio = 2.48, 95% confidence interval = 2.18-2.81, P < 0.001). The difference in pain relief at 2 hours did not significantly favor telcagepant over triptans or vice versa (odds ratio = 0.76, 95% confidence interval = 0.57-1.01, P = 0.061). These findings indicate that telcagepant can be effective for treating acute migraine. Calcitonin gene-related peptide receptor antagonists represent a potentially important alternative means of treating acute migraine.

    Topics: Acute Disease; Azepines; Calcitonin Gene-Related Peptide Receptor Antagonists; Humans; Imidazoles; Migraine Disorders; Oxazolidinones; Serotonin 5-HT1 Receptor Agonists; Treatment Outcome; Triazoles; Tryptamines

2015
Management of acute and chronic migraine.
    Current opinion in supportive and palliative care, 2012, Volume: 6, Issue:2

    We highlight the recent clinical trials for the management of acute and chronic migraine.. In women with menstrual migraine, triptans seem to be well tolerated irrespective of whether or not patients are taking oestrogen-containing contraceptives or have comorbidities that indicate increased cardiovascular risk. The new acute drug, telcagepant, a calcitonin gene-related peptide (CGRP) antagonist, is safe for long-term use (up to 18 months) in migraine patients with stable coronary artery disease in whom the use of triptans is not advisable. From the pooled analysis of the two Phase III Research Evaluating Migraine Prophylaxis Therapy studies of onabotulinumtoxinA (BOTOX) in chronic migraineurs, it clearly emerged that efficacy increases overtime (up to 56 weeks) and paralleled self-perceived improvement in quality of life. Effectiveness was also observed in patients with severely disabling headaches, who met criteria for triptan abuse and were refractory to several prophylactic treatments. Finally, combination of preventive pharmacological agents with different action mechanisms may be the next frontier in therapeutic advancements for treating migraine.. Although triptans are safe and well tolerated, CGRP antagonists may be an option for nonresponsive patients or those in whom the use of triptans is not advisable. New drugs and combinations of old therapeutic options may help patients with severe forms of headache.

    Topics: Acute Disease; Azepines; Botulinum Toxins, Type A; Calcitonin Gene-Related Peptide Receptor Antagonists; Chronic Disease; Humans; Imidazoles; Migraine Disorders; Randomized Controlled Trials as Topic; Tryptamines

2012

Trials

1 trial(s) available for telcagepant and Acute-Disease

ArticleYear
Randomized, controlled trial of telcagepant for the acute treatment of migraine.
    Neurology, 2009, Sep-22, Volume: 73, Issue:12

    The neuropeptide calcitonin gene-related peptide (CGRP) plays a key role in migraine pathophysiology. In this large phase 3 clinical trial, we sought to confirm the efficacy of telcagepant, the first orally bioavailable CGRP receptor antagonist.. Adults with migraine with or without aura (International Headache Society criteria) treated a moderate or severe attack with oral telcagepant 50 mg (n = 177), 150 mg (n = 381), 300 mg (n = 371), or placebo (n = 365) in a randomized, double-blind trial. The 5 co-primary endpoints were pain freedom, pain relief, and absence of photophobia, absence of phonophobia, and absence of nausea, all at 2 hours postdose. The key secondary endpoint was 2-24 hour sustained pain freedom. The prespecified primary efficacy analyses evaluated the 150 mg and 300 mg groups; the 50-mg group was included on an exploratory basis to further characterize the dose response but was not prespecified for analysis. Tolerability was assessed by adverse experience reports.. Telcagepant 300 mg was more effective (p

    Topics: Acute Disease; Adult; Azepines; Calcitonin Gene-Related Peptide; Calcitonin Gene-Related Peptide Receptor Antagonists; Dose-Response Relationship, Drug; Double-Blind Method; Endpoint Determination; Female; Humans; Hyperacusis; Imidazoles; Male; Middle Aged; Migraine Disorders; Nausea; Outcome Assessment, Health Care; Pain Measurement; Photophobia; Placebos; Quality of Life; Receptors, Calcitonin Gene-Related Peptide; Surveys and Questionnaires; Treatment Outcome

2009